Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

ACR Blue Ribbon Panel Response to the AJR Commentary by Shellock and Crues on the ACR White Paper on MR Safety
Borgstede, James P. , Barkovich, A. James , Bell, Charlotte , Bradley, William G., Felmlee, Joel P. , Froelich, Jerry , Kaminski, Ellisa M., Keeler, Elaine K., Lester, James W., Scoumis, Elizabeth A., Zaremba, L, Zinninger, M., Kanal, Emanuel

American Journal of Roentgenology | March 5, 2013 | Volume: 180 | Issue: 1 | Pages: 31-35

10.2214/ajr.180.1.1800031 | PMID 12490473 Get It

Towards a Universal Clinical Genomics Database: The 2012 International Standards for Cytogenomic Arrays Consortium Meeting
Riggs, Erin Rooney , Wain, Karen E. , Riethmaier, Darlene, Savage, Melissa, Smith‐Packard, Bethanny, Kaminsky, Erin B., Rehm, Heidi L. , Martin, Christa Lese , Ledbetter, David H. , Faucett, W. Andrew, Rehm, Heidi L

Human Mutation | March 5, 2013 | Volume: 34 | Issue: 6 | Pages: 915-919

10.1002/humu.22306 | PMID 23463607 Get It

Letter: complications of coeliac disease despite a gluten‐free diet – authors' reply
Lebwohl, Benjamin , Granath, Fredrik, Ekbom, Anders , Montgomery, Scott , Murray, Joseph A. , Green, P. H. R., Ludvigsson, Jonas F. , Rubio‐Tapia, Alberto , Murray, J A , Montgomery, Scott

Alimentary Pharmacology & Therapeutics | March 5, 2013 | Volume: 37 | Issue: 7 | Pages: 762-763

10.1111/apt.12243 | PMID 23458542 Get It

Letter: an allergic phenotype in patients with eosinophilic oesophagitis and asthma – authors' reply
Harer, Kimberly, Katzka, David A.

Alimentary Pharmacology & Therapeutics | March 5, 2013 | Volume: 37 | Issue: 7 | Pages: 756-757

10.1111/apt.12241 | PMID 23458536 Get It

Teaching Neuro Images : PET-CT hypermetabolism paralleling muscle hyperactivity in stiff-person syndrome
O’Toole, Orna , Tracy, Jennifer A., McKeon, Andrew , Murphy, Robert L. , McKeon, Andrew

Neurology | March 5, 2013 | Volume: 80 | Issue: 10 | Pages: No page available

10.1212/wnl.0b013e3182840bad | PMID 23460625 Get It

Mortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: A Prospective Study
Barbaresi, William J. , Colligan, Robert C., Weaver, Amy L. , Voigt, Robert G. , Killian, Jill M. , Katusic, Slavica K.

Pediatrics | March 5, 2013 | Volume: 131 | Issue: 4 | Pages: 637-644

10.1542/peds.2012-2354 | PMID 23460687 Get It

OBJECTIVE: We examined long-term outcomes of attention-deficit/hyperactivity disorder (ADHD) in a population-based sample of childhood ADHD cases and controls, prospectively assessed as adults. METHODS: Adults with childhood ADHD and non-ADHD controls from the same birth cohort (N = 5718) were invited to participate in a prospective outcome study. Vital status was determined for birth cohort members. Standardized mortality ratios (SMRs) were constructed to compare overall and cause-specific mortality between childhood ADHD cases and controls. Incarceration status was determined for childhood ADHD cases. A standardized neuropsychiatric interview was administered. RESULTS: Vital status for 367 childhood ADHD cases was determined: 7 (1.9%) were deceased, and 10 (2.7%) were currently incarcerated. The SMR for overall survival of childhood ADHD cases versus controls was 1.88 (95% confidence interval [CI], 0.83–4.26; P = .13) and for accidents only was 1.70 (95% CI, 0.49–5.97; P = .41). However, the cause-specific mortality for suicide only was significantly higher among ADHD cases (SMR, 4.83; 95% CI, 1.14–20.46; P = .032). Among the childhood ADHD cases participating in the prospective assessment (N = 232; mean age, 27.0 years), ADHD persisted into adulthood for 29.3% (95% CI, 23.5–35.2). Participating childhood ADHD cases were more likely than controls (N = 335; mean age, 28.6 years) to have ≥1 other psychiatric disorder (56.9% vs 34.9%; odds ratio, 2.6; 95% CI, 1.8–3.8; P < .01). CONCLUSIONS: Childhood ADHD is a chronic health problem, with significant risk for mortality, persistence of ADHD, and long-term morbidity in adulthood.
Cross‐species analysis of nicotine‐induced proteomic alterations in pancreatic cells
Kadiyala, Vivek, Banks, Peter A. , Conwell, Darwin L. , Paulo, João A. , Urrutia, Raúl , Steen, Hanno

PROTEOMICS | March 5, 2013 | Volume: 13 | Issue: 9 | Pages: 1499-1512

10.1002/pmic.201200492 | PMID 23456891 Get It

Toxic compounds in tobacco, such as nicotine, may adversely affect pancreatic function. We aim to determine nicotine‐induced protein alterations in pancreatic cells, thereby revealing links between nicotine exposure and pancreatic disease. We compared the proteomic alterations induced by nicotine treatment in cultured pancreatic cells (mouse, rat, and human stellate cells and human duct cells) using MS‐based techniques, specifically SDS‐PAGE (gel) coupled with LC‐MS/MS and spectral counting. We identified thousands of proteins in pancreatic cells, hundreds of which were identified exclusively or in higher abundance in either nicotine‐treated or untreated cells. Interspecies comparisons of stellate cell proteins revealed several differentially abundant proteins (in nicotine treated versus untreated cells) common among the three species. Proteins appearing in all nicotine‐treated stellate cells include amyloid beta (A4), procollagen type VI alpha 1, integral membrane protein 2B, and toll‐interacting protein. Proteins that were differentially expressed upon nicotine treatment across cell lines were enriched in certain pathways, including nicotinic acetylcholine receptor, cytokine, and integrin signaling. At this analytical depth, we conclude that similar pathways are affected by nicotine, but alterations at the protein level among stellate cells of different species vary. Further interrogation of such pathways will lead to insights into the potential effect of nicotine on pancreatic cells at the biomolecular level and the extension of this concept to the effect of nicotine on pancreatic disease.
Faculty Opinions recommendation of Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Fernández-Zapico, Martín E.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 4, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717978653.793471498 Get It

Assessments of the extent to which health‐care providers involve patients in decision making: a systematic review of studies using the OPTION instrument
Couët, Nicolas, Desroches, Sophie , Robitaille, Hubert , Vaillancourt, Hugues, Turcotte, Stéphane , Elwyn, Glyn , Légaré, France , LeBlanc, Annie

Health Expectations | March 4, 2013 | Volume: 18 | Issue: 4 | Pages: 542-561

10.1111/hex.12054 | PMID 23451939 Get It

Abstract Background We have no clear overview of the extent to which health‐care providers involve patients in the decision‐making process during consultations. The Observing Patient Involvement in Decision Making instrument ( OPTION ) was designed to assess this. Objective To systematically review studies that used the OPTION instrument to observe the extent to which health‐care providers involve patients in decision making across a range of clinical contexts, including different health professions and lengths of consultation. Search strategy We conducted online literature searches in multiple databases (2001–12) and gathered further data through networking. Inclusion criteria (i) OPTION scores as reported outcomes and (ii) health‐care providers and patients as study participants. For analysis, we only included studies using the revised scale. Data extraction Extracted data included: (i) study and participant characteristics and (ii) OPTION outcomes (scores, statistical associations and reported psychometric results). We also assessed the quality of OPTION outcomes reporting. Main results We found 33 eligible studies, 29 of which used the revised scale. Overall, we found low levels of patient‐involving behaviours: in cases where no intervention was used to implement shared decision making ( SDM ), the mean OPTION score was 23 ± 14 (0–100 scale). When assessed, the variables most consistently associated with higher OPTION scores were interventions to implement SDM ( n = 8/9) and duration of consultations ( n = 8/15). Conclusions Whatever the clinical context, few health‐care providers consistently attempt to facilitate patient involvement, and even fewer adjust care to patient preferences. However, both SDM interventions and longer consultations could improve this.
Randomised clinical trial: the effects of d aikenchuto, TU ‐100, on gastrointestinal and colonic transit, anorectal and bowel function in female patients
Iturrino, Johanna , Camilleri, Michael , Wong, Banny S., Nord, Sara J. Linker, Burton, Duane D. , Zinsmeister, Alan R.

Alimentary Pharmacology & Therapeutics | March 4, 2013 | Volume: 37 | Issue: 8 | Pages: 776-785

10.1111/apt.12264 | PMID 23451764 Get It

Summary Background Daikenchuto, a Japanese herbal medicine used for post‐operative ileus and constipation, dose dependently stimulates gastrointestinal ( GI ) motility and decreases rectal compliance and sensation. Effects of TU ‐100 (commercial form of daikenchuto) in adults with constipation are unknown. Aim To compare the effects of oral TU ‐100, 2.5 g t.d.s. or 5 g t.d.s. and placebo t.d.s. on GI and colonic transit ( CT ), rectal compliance ( RC ) and sensation thresholds ( RST ), anal sphincter pressures ( ASP ) and bowel function in female patients with functional constipation ( FC ). Methods We conducted a single‐centre, randomised, parallel‐group, double‐blind, pharmacodynamic study; 45 female patients with FC without evidence of rectal evacuation disorder were assigned to 28 days' treatment with oral placebo or TU ‐100 (Tsumura USA, Princeton, NJ, USA). Demographic data and CT were measured at baseline and randomisation stratified by baseline CT (GC> or <1.9) and by BMI (<25 or ≥25 kg/m 2 ). At the end of treatment period, we measured GI and CT by scintigraphy, RST and RC by barostat, ASP by manometry, psychosensory sensations, bowel function by daily diary and quality of life ( QOL ). The study had power to detect effect sizes of 33% ( CT ), 40% ( RC ) and 46% ( RST ). Statistical analysis included BMI as covariate. Results TU ‐100 had no significant effects on GI or CT , RC , ASP , recto‐anal pressure difference, or RST . The 5 g t.d.s./day dose was associated with lower RST for first sensation and gas (unadjusted P : 0.045 and 0.024 respectively). There were no treatment effects on psychosensory symptoms, stool frequency, stool consistency or QOL . Conclusion Mechanisms underlying the observed clinical benefit of TU ‐100 remain unclear ( ClinicalTrials.gov NCT01139216).